Table 4 Odds ratios of esophageal cancer in relation to use of anti-diabetic drugs
From: Risk of esophagus cancer in diabetes mellitus: a population-based case-control study in Taiwan
Use of anti-diabetic drugs | Case | Control | Odds ratio (95% CI) | |
|---|---|---|---|---|
| Â | Number (%) | Model 1 | Model 2 | |
Insulins | Â | Â | Â | Â |
never use | 7(12.3) | 69(31.1) | 1.00 | 1.00 |
ever use | 50(87.7) | 153(68.9) | 3.27(1.40-7.60) | 2.58(1.08-6.15) |
Metformin | Â | Â | Â | Â |
never use | 5(8.77) | 43(19.4) | 1.00 | 1.00 |
ever use | 52(91.2) | 179(80.6) | 2.34(0.87-6.24) | 2.84(0.99-8.18) |
Sulfonylureas | Â | Â | Â | Â |
never use | 4(7.02) | 38(17.1) | 1.00 | 1.00 |
ever use | 53(92.9) | 184(82.9) | 2.75(0.94-8.10) | 3.80(1.16-12.5) |
Thiazolidinediones | Â | Â | Â | Â |
never use | 49(86.0) | 180(81.1) | 1.00 | 1.00 |
ever use | 8(14.0) | 42(18.9) | 0.65(0.28-1.49) | 1.11(0.46-2.65) |
Alpha-glucosidase inhibitors | Â | Â | Â | Â |
never use | 48(84.2) | 188(84.7) | 1.00 | 1.00 |
ever use | 9(15.8) | 34(15.3) | 1.00(0.44-2.24) | Â |